Neurosciences articles for Australia

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 90

Article ‘Count’ for Neurosciences.

Journal Count Share
1 0.07
Ultrasound Active Piezoelectric Nanostimulators for Long-Acting Wireless Deep Brain Electric Stimulation to Inhibit Epileptic Seizures 0.07
2 0.58
BLOC1S1 variants cause lysosomal and autophagic defects resulting in a hypomyelinating leukodystrophy with epileptic encephalopathy 0.05
SMN1 variants identified by false-positive SMA newborn screening tests: Therapeutic hurdles and functional and epidemiological solutions 0.53
12 3.31
Stroke Etiologies With Intravenous Thrombolysis before Thrombectomy and Functional Outcomes in Anterior Circulation Large Vessel Occlusion 0.11
Effects of Blood Pressure Lowering Across Hematoma Volume in Acute Intracerebral Hemorrhage: Pooled Analysis of the Four INTERACT and ATACH-2 Trials 0.37
Thrombectomy versus Medical Management for Pediatric Acute Ischemic Stroke Due to Isolated M2 Occlusion: A Multicenter Cohort Study 0.04
Turning Slowly Predicts Future Diagnosis of Parkinson's Disease: A Decade‐Long Longitudinal Analysis 0.20
Epstein–Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset 0.79
Mutations in the Key Autophagy Tethering Factor scpEPG5/scp Link Neurodevelopmental and Neurodegenerative Disorders Including Early‐Onset Parkinsonism 0.01
From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis 0.09
Clinical and Molecular Genetic Characterization of Landau Kleffner Syndrome: An Observational Cohort and Experimental Study 0.31
iHCN2/i‐Associated Neurodevelopmental Disorders: Data from Patients and iXenopus/i Cell Models 0.25
Intravenous Glyburide in Medical and Endovascular‐Treated Large‐Core Stroke: A Subgroup Analysis of the scpCHARM/scp Randomized Clinical Trial 0.11
Adjunctive scpThrombolytics/scp After Successful Endovascular Reperfusion: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials 0.05
The FindMNDBiomarker Program: Protein Changes in Motor Neuron Disease/Amyotrophic Lateral Sclerosis Postmortem Tissue and Biofluids 1.00
1 0.03
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment 0.03
4 4.00
Core Practice Principles: A mixed-methods approach to determine what drives the use of seated trunk control assessments in spinal cord injury clinical and research practice. 1.00
Trajectory of Mobility Function Decline for People With Motor Neuron Disease 1.00
Understanding multidimensional apathy in traumatic brain injury 1.00
Quality and outcomes of acute stroke care for people with and without aphasia 1.00
1 0.08
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study 0.08
9 3.60
Region-specific variations in the cerebrovasculature underlie disease progression in Parkinson's disease 1.00
PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson’s disease models 0.75
Tipping the balance: the PD1-axis as modulator in chronic inflammatory demyelinating polyneuropathy 0.04
Associations between epilepsy-related polygenic risk and brain morphology in childhood 0.09
Molecular and clinical spectrum of epilepsy-dyskinesia syndromes: a cross-sectional study of 609 patients 0.06
Neuronal α-synuclein toxicity is the key driver of neurodegeneration in multiple system atrophy 0.56
Twins with temporal lobe epilepsy: genetic contributions to hippocampal sclerosis and other subtypes 1.00
Charcot-Marie-Tooth disease type 1E: clinical natural history and molecular impact of iPMP22/i variants 0.08
Redefining diagnostic lesional status in temporal lobe epilepsy with artificial intelligence 0.03
1 0.03
The NEON (Nerve rEpair Or Not) trial: a randomized controlled trial of microsurgical repair iversus/i nerve alignment for digital nerve injury 0.03
1 0.15
C5aR1 inhibition alleviates cranial radiation-induced cognitive decline. 0.15
1 0.64
Ferroptosis susceptibility in hippocampal neural precursor cells influences neurogenesis and memory across aging 0.64
1 0.03
Electroencephalogram Features Distinguish Cases of Cerebral Malaria Among Malawian Children With Fever and Coma 0.03
1 0.75
Nocturnal ants navigate using a time-compensated lunar compass 0.75
1 1.00
Central amygdala neuropeptide Y neurons drive hedonic ingestive behaviour independent of energy homeostasis 1.00
1 0.08
Multivariate Brain-Blood Signatures in Early-Stage Depression and Psychosis 0.08
5 0.11
Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours 0.04
Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke 0.01
Levodopa Added to Stroke Rehabilitation 0.01
Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours 0.04
Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy 0.02
1 0.06
Biallelic variants in ARHGAP19 cause a progressive inherited motor-predominant neuropathy 0.06
1 0.03
Amyloidosis of bridging veins is a pathologic feature of Alzheimer’s disease 0.03
2 1.02
Stable Mechanoreceptive Somatotopy in Chronic Low Back Pain: Is Cortical Map Reorganization a Myth? 0.06
Bed nucleus of stria terminalis enkephalin neurons contribute to depletion-induced salt appetite 0.95
5 2.23
Ageing does not impair motor neuron adaptations: comparable motor unit responses to strength training in young and older adults 0.08
Vagal sensory neurones directly synapse onto parasympathetic motor (DMV) neurones 1.00
First in‐human microelectrode recordings of vagus nerve activity in heart failure 0.20
Profiling muscle mass, function and molecular signalling in females aged 18–80 years and their associations with sex hormones 0.83
Acute intermittent hypercapnic hypoxia augments left ventricular contractility 0.11
1 0.93
Epigenetic, ribosomal, and immune dysregulation in paediatric acute-onset neuropsychiatric syndrome 0.93
3 1.02
Convergent evolution of scavenger cell development at brain borders 0.91
Quantum spin resonance in engineered proteins for multimodal sensing 0.06
Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis 0.05
14 4.06
Tau T205 phosphorylation modulates engram cell recruitment and remote memory in mice 1.00
Blood flow patterns in mice are regulated by interpericyte tunneling nanotubes connecting functionally-opposite neuronal areas 0.78
Dual-stiffness nanoparticles for compartment-specific drug delivery in stroke 0.06
A reversible allosteric inhibitor of GlyT2 for neuropathic pain without on-target side effects 0.59
Identification of and NLRP3 inflammasome activation in Alzheimer’s disease retina 0.13
4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy 0.02
The Genetic Architecture of the Human Corpus Callosum and its Subregions 0.08
Sex-specific associations of gene expression with Alzheimer’s disease neuropathology and ante-mortem cognitive performance 0.02
Estrogen-related receptor gene expression associates with sex differences in cortical atrophy in isolated REM sleep behavior disorder 0.11
Integrating artificial intelligence and optogenetics for Parkinson’s disease diagnosis and therapeutics in male mice 0.07
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial 0.07
A human brain network linked to restoration of consciousness after deep brain stimulation 0.05
Variable and interactive effects of Sex, APOE ε4 and TREM2 on the deposition of tau in entorhinal and neocortical regions 0.08
Cholinergic basal forebrain neurons regulate vascular dynamics and cerebrospinal fluid flux 1.00
1 0.10
Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis 0.10
3 0.10
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration 0.02
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial 0.06
AI-driven reclassification of multiple sclerosis progression 0.02
5 2.64
White matter pathways mediating dorsolateral prefrontal TMS therapy for depression 0.50
Investigating the methodological foundation of lesion network mapping 0.17
Increased neural excitability and glioma synaptic activity drives glioma proliferation in human cortex 0.96
Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy 0.97
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, genotype and sex 0.05
1 0.08
In vivo 7 Tesla MRI of non-human primate intracortical microvascular architecture 0.08
1 0.04
Associations between epileptic seizures in pregnancy and adverse pregnancy outcomes: A systematic review and meta-analysis 0.04
1 0.03
ATP13A2 restrains macrophage NLRP3 inflammasome activation to repress neurodegeneration via modulating mitochondrial homeostasis 0.03
1 0.03
Homing pigeon navigation relies on superparamagnetic macrophages under overcast conditions 0.03
2 0.18
Enteric botulinum neurotoxins facilitate infection by Salmonella and Shigella 0.08
CHCHD2 mutant mice link mitochondrial deficits to PD pathophysiology 0.10
3 0.24
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial 0.06
Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication 0.10
Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial 0.09
1 0.46
Effects of blood pressure lowering in relation to time in acute intracerebral haemorrhage: a pooled analysis of the four INTERACT trials 0.46
2 0.06
Asundexian for Secondary Stroke Prevention 0.02
Risdiplam in Presymptomatic Spinal Muscular Atrophy 0.05

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.